Drugmaker Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, CEO Erez Israeli said in a press briefing on Wednesday. The launch plans for the generic version of semaglutide, which is the active ingredient of Novo's Wegovy and Ozempic, comes at a time when drugmakers are racing to grab a share of the global obesity drugs market that is expected to be valued at $150 billion by early 2030s.
- News Source Indiatimes (Click to view full news): CLICK HERE
0 Comments:
Leave a Reply